Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in hihg-risk patients with and without metabolic syndrome.

Averna, M.; Missault, L.; Vaverkova, H.; Farnier, M.; Viigimaa, M. et al. (2011). Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in hihg-risk patients with and without metabolic syndrome. Diabetes and Vascular Disease Research, 1−9.
ajakirjaartikkel
Averna, M.; Missault, L.; Vaverkova, H.; Farnier, M.; Viigimaa, M. et al.
Diabetes and Vascular Disease Research
1479-1641
2011
19
Ilmunud
1.1. Teadusartiklid, mis on kajastatud Web of Science andmebaasides Science Citation Index Expanded, Social Sciences Citation Index, Arts & Humanities Citation Index ja/või andmebaasis Scopus (v.a. kogumikud)
ERIH

Viited terviktekstile

Lisainfo